On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

DexCom DXCM recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States ...

Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience.

With its TMR sticks, removable faceplate, switchable triggers, charging dock, Xbox compatibility, and more, the G7 Pro is ...

Ultrahuman has expanded its digital health ecosystem with the US launch of M2 Live, an updated metabolic health platform that integrates continuous glucose data from Abbott’s over-the-counter Lingo ...

Ultrahuman has launched M2 Live in the US, combining Abbott's Lingo glucose monitor with AI-powered metabolic insights at a lower entry price.

The FDA expanded clearance of Dexcom's Stelo Glucose Biosensor System to individuals aged 2 years and older who do not use insulin.

Apple Watch blood sugar tracking remains unconfirmed. Here's the latest on the timeline, patents, technical challenges, and ...

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Abbott's CGM sales rose 7.5% to $2 billion in Q1, impacted by tender renewal delays and tough comparisons. ABT expects CGM to return to double-digit growth in Q2, supported by market trends and ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...